Last reviewed · How we verify

NCT04882592

Noninvasive Spinal Neuromodulation Enables Locomotor Recovery in Individuals With Cerebral Palsy

Status unknown Phase 1 Last updated 4 April 2023
What this trial tests

Phase 1 trial testing SCiP in Cerebral Palsy in 50 participants. Status unknown.

Timeline
15 May 2021
Primary endpoint
1 December 2023
1 December 2024

Quick facts

Lead sponsorSpineX Inc.
PhasePhase 1
StatusStatus unknown
Study typeINTERVENTIONAL
Allocationna
Designcrossover
Maskingsingle
Primary purposetreatment
Enrollment50
Start date15 May 2021
Primary completion1 December 2023
Estimated completion1 December 2024
Sites1 location across United States

Drugs / interventions tested

Conditions studied

Sponsor

SpineX Inc.

Who can join

Adults 2 to 75, any sex, with Cerebral Palsy. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Assessing the effects of noninvasive spinal cord neuromodulation on improving function in individuals with cerebral palsy

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

  1. A pilot study combining noninvasive spinal neuromodulation and activity-based neurorehabilitation therapy in children with cerebral palsy.
    Hastings S, Zhong H, Feinstein R, Zelczer G, et al · · 2022 · cited 14× · PMID 36198701 · DOI 10.1038/s41467-022-33208-w

Verify or expand the search:

Other trials of SCiP

Trials testing the same drug.

Other recruiting trials for Cerebral Palsy

Currently open trials in the same condition.

Other SpineX Inc. trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04882592.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing